PCOS Renamed PMOS: What It Is, Why It Matters, And What Changes Next

Add as a preferred source on Google

For decades, women were told they had polycystic ovary syndrome, a name that pointed directly at the ovaries and at cysts as the defining feature of their condition. Many of those women did not even have cysts. What they had was a complex, full-body hormonal and metabolic disorder that the name was fundamentally failing to describe.

That has now officially changed.

Photo Credit: Canva

What Happened

On May 12, 2026, at the European Congress of Endocrinology in Prague, experts announced that polycystic ovary syndrome will now be called polyendocrine metabolic ovarian syndrome - PMOS. The decision, detailed in The Lancet, was informed by tens of thousands of survey responses from patients and health professionals and coordinated by 56 academic, clinical, and patient organisations.

The new name recognises that the condition is not primarily a gynaecological disorder but rather a complex, multisystem condition involving endocrine, metabolic, reproductive, dermatological, and psychological health.

Why The Old Name Was A Problem

Photo Credit: Canva

The name PCOS was not just imprecise; it was actively causing harm.

The condition affecting more than 170 million women worldwide, or more than one in eight, was widely misunderstood to be "all about ovarian cysts." The name PCOS reduced a complex, long-term hormonal or endocrine disorder to a misunderstanding about cysts and an overt focus on ovaries. This contributed to missed diagnoses and inadequate treatment.

For decades, the term polycystic ovary syndrome was widely recognised as inaccurate and limiting. Despite its name, many patients do not have ovarian cysts, which obscures the condition's broader health implications. This mischaracterisation had tangible consequences: delayed diagnoses, fragmented care, stigma, and missed opportunities for early intervention in metabolic and cardiovascular risks.

14 Years, 22,000 Voices

This was not a decision made quickly or lightly. The PCOS community underwent the most robust and extensive disease-renaming process in history. Building on earlier surveys administered in 2017 and 2023, a team led by Professor Helena Teede at Monash University in Australia developed a third survey administered to nearly 15,000 stakeholders in 2025. Overall, about 22,000 people across the globe - doctors, researchers, patients, and charities - shared their thoughts on a new name.

Asked what they wanted a new name to accomplish, the primary response was avoiding stigma, followed by ease of communication and scientific accuracy. Participants preferred an accurate, descriptive name and expressed a strong interest in incorporating the endocrine system's involvement in the condition.

What PMOS Means

Photo Credit: Magnific

The new name - polyendocrine metabolic ovarian syndrome - does considerably more explanatory work than its predecessor. PMOS is characterised by fluctuations in hormones, with impacts on weight, metabolic and mental health, skin, and the reproductive system. Breaking down the name itself: polyendocrine acknowledges the multiple hormonal systems involved; metabolic recognises the condition's significant impact on insulin resistance, weight, and cardiovascular risk; ovarian retains the connection to reproductive health; and syndrome reflects that it is a cluster of features rather than a single disease.

What Changes Next

The name has changed. The infrastructure will follow. Over the next three years, PMOS will be incorporated into clinical guidelines, international disease classifications, and professional training curricula. Global campaigns will inform healthcare providers, policymakers, and the public, and resources like the AskPCOS app will be rebranded to reflect the new terminology.

PMOS will be fully implemented in the 2028 International Guideline update. Organisers expect the transition to enhance diagnostic accuracy, reduce stigma, and align medical language with current scientific understanding.

Bottomline

A name is not just a label; it shapes how a condition is understood, researched, funded, and treated. For 170 million women, PCOS was a name that pointed at the wrong thing, for too long. PMOS points at the right one. That shift - 14 years, 22,000 voices, and one landmark paper in The Lancet in the making, is the kind of change that does not make headlines for long but quietly improves lives for decades.

Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.